Candriam S.C.A. Has $35.97 Million Stake in IDEXX Laboratories, Inc. $IDXX

Candriam S.C.A. raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 26.6% in the first quarter, Holdings Channel reports. The fund owned 64,015 shares of the company’s stock after buying an additional 13,456 shares during the quarter. Candriam S.C.A.’s holdings in IDEXX Laboratories were worth $35,969,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Beacon Investment Advisory Services Inc. boosted its holdings in IDEXX Laboratories by 11.9% in the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after purchasing an additional 6,710 shares during the period. Nordea Investment Management AB increased its holdings in shares of IDEXX Laboratories by 114.1% during the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after purchasing an additional 8,845 shares during the period. Procyon Advisors LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $1,966,000. Diversified Trust Co. raised its position in shares of IDEXX Laboratories by 223.5% during the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock valued at $2,841,000 after buying an additional 2,901 shares during the last quarter. Finally, Mirabella Financial Services LLP lifted its stake in shares of IDEXX Laboratories by 156.2% in the third quarter. Mirabella Financial Services LLP now owns 4,401 shares of the company’s stock valued at $2,806,000 after buying an additional 2,683 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock traded up $4.97 during midday trading on Friday, hitting $563.57. 612,524 shares of the company were exchanged, compared to its average volume of 657,640. The firm has a 50 day simple moving average of $555.09 and a 200-day simple moving average of $604.44. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm has a market cap of $44.45 billion, a P/E ratio of 41.50, a PEG ratio of 3.08 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several recent research reports. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 25th. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Finally, UBS Group reduced their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.